Patents Assigned to Takeda Pharmaceutical Company Limited
  • Publication number: 20230340057
    Abstract: The invention relates to parathyroid hormone (PTH) variants and pharmaceutical compositions comprising same. The invention further relates to PTH compositions with improved serum half-life and peak-trough ratios, and methods of controlling serum calcium levels with the PTH variants and compositions of the invention. The invention further relates to methods of treating hypoparathyroidism and/or hypocalcemia due to hypoparathyroidism with the PTH variants and compositions of the invention.
    Type: Application
    Filed: March 2, 2023
    Publication date: October 26, 2023
    Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED
    Inventors: Clark PAN, Angela NORTON, Kevin HOLMES, David LLOYD, Bryan GOODWIN, Rongxin SHI, Sujit JAIN, Chuan SHEN
  • Publication number: 20230340159
    Abstract: The invention relates to COnditional Bispecific Redirected Activation constructs, or COBRAs, that are administered in an active pro-drug format. Upon exposure to tumor proteases, the constructs are cleaved and activated, such that they can bind one or more tumor target antigens (TTAs) as well as CD3, thus recruiting T cells expressing CD3 to the tumor, resulting in treatment. In some embodiments, the tumor target antigen includes B7H3, CA9 (CAIX), EGFR, EpCAM, FOLR1, HER2, LyPD3, and/or Trop2.
    Type: Application
    Filed: February 22, 2023
    Publication date: October 26, 2023
    Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED
    Inventors: Robert B. DuBridge, Tseng-hui Timothy Chen, Patricia A. Culp, Chad Michael May, Danielle Dettling, Jeremiah Daniel Degenhardt
  • Publication number: 20230340697
    Abstract: Provided are compositions and methods for preparing and identifying antibodies having CDR3s that vary in sequence and in length from very short to very long which in certain embodiments may bind to a carbohydrate moiety or the active site of an enzyme. Libraries coding for antibodies with the CDR3s are also provided. The libraries can be provided by modifying a pre-existing nucleic acid library.
    Type: Application
    Filed: January 27, 2023
    Publication date: October 26, 2023
    Applicant: Takeda Pharmaceutical Company Limited
    Inventor: Robert Charles Ladner
  • Publication number: 20230340054
    Abstract: The present invention provides, among other things, compositions and methods for prophylaxis and treatment of autoimmune disease. The present invention is based, in part, on the surprising discovery that a human interleukin-2 mutein activates proliferation of regulatory T cells. In one aspect, the present invention provides compositions and methods for proliferation of regulatory T cells. In another aspect, a human interleukin-2 (IL-2) mutein comprising an amino acid sequence that is at least 90% identical to the wild type IL-2 protein is described, wherein the IL-2 mutein has at least one amino acid substitution selected from a group consisting of T111H, T37Y, E15T, M23L, P34F, E68F and E62A.
    Type: Application
    Filed: August 31, 2021
    Publication date: October 26, 2023
    Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED
    Inventors: Shuichi MIYAKAWA, Dnyaneshwar Eknath Warude, Michael SHAW, James l. KIM, Ertan ERYILMAZ, Yosuke SATO
  • Publication number: 20230340150
    Abstract: Plasma kallikrein binding proteins and methods of using such proteins are described.
    Type: Application
    Filed: October 4, 2022
    Publication date: October 26, 2023
    Applicant: Takeda Pharmaceutical Company Limited
    Inventors: Daniel J. Sexton, Malini Viswanathan
  • Patent number: 11793812
    Abstract: Methods for treating uterine fibroids, endometriosis, adenomyosis, or heavy menstrual bleeding in a subject, which include administering to the subject from 10 mg to 60 mg per day of N-(4-(1-(2,6-difluorobenzyl)-5-((dimethylamino)methyl)-3-(6-methoxy-3-pyridazinyl)-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-N?-methoxyurea, and from 0.01 mg to 5 mg per day of a hormone replacement medicament. The present disclosure has methods for reducing menstrual bleeding in a subject, reducing bone mineral density loss in a subject caused by administering a GnRH antagonist to the subject, suppressing sex hormones in a subject, reducing vasomotor symptoms or hot flashes in a subject, and reducing symptoms of decreased libido in a subject having uterine fibroids, endometriosis, or adenomyosis.
    Type: Grant
    Filed: May 11, 2021
    Date of Patent: October 24, 2023
    Assignees: Sumitomo Pharma Switzerland GmbH, Takeda Pharmaceutical Company Limited
    Inventors: Brendan Mark Johnson, Lynn Seely, Paul N. Mudd, Jr., Susan Wollowitz, Mark Hibberd, Masataka Tanimoto, Vijaykumar Reddy Rajasekhar, Mayukh Vasant Sukhatme
  • Patent number: 11793721
    Abstract: In some embodiments, a reconstitution or medicinal fluid delivery device includes a transfer engine including two fluidly connected spikes, each configured to pierce a container. A check valve may be disposed between the two spikes to allow unidirectional flow from one container to the other. Physical access to a fluid outlet may be obstructed by a housing until the reconstitution or medicinal fluid delivery device is actuated, whereupon physical access to the fluid outlet is permitted. The reconstitution or medicinal fluid delivery device may be placed on a flat surface and actuated with force applied in a single direction toward the flat surface.
    Type: Grant
    Filed: March 5, 2021
    Date of Patent: October 24, 2023
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Joseph M. Giamo, Thomas Boyajian, Amey Mathakari, Anh Nguyen, Dhairya Kiritkumar Mehta
  • Patent number: 11795216
    Abstract: The invention relates to neutralizing antibodies of GM-CSF and compositions comprising the same for use in the treatment of inflammatory disorders such as rheumatoid arthritis according to specific dosing regimen. The invention relates also to neutralizing antibodies of GM-CSF and compositions comprising the same for use in the treatment of pain, e.g. pain experienced in inflammatory disorders such as rheumatoid arthritis, according to specific dosage regimen.
    Type: Grant
    Filed: August 17, 2020
    Date of Patent: October 24, 2023
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Thomas Wagner, Malin Carlsson, Margit Staum Kaltoft
  • Patent number: 11795178
    Abstract: The present invention provides a production method of a thienopyrimidine derivative or a salt thereof which has a gonadotropin releasing hormone (GnRH) antagonistic action with high quality in high yield. The present invention provides a method of producing a thienopyrirnidine derivative, which comprises reacting 6-(4-aminophenyl)-1-(2,6-difluorobenzyl)-5-dimethylaminomethyl-3-(6-methoxypyridazin-3-yl)thieno[2,3-d]pyrimidine-2,4(1H,3H)-dione or salt thereof, 1,1?-carbonyldiimidazole or a salt thereof and methoxyamine or a salt thereof, and the like.
    Type: Grant
    Filed: March 14, 2022
    Date of Patent: October 24, 2023
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Koichiro Fukuoka, Kazuhiro Miwa, Tsuyoshi Sasaki, Fumiya Komura
  • Patent number: 11793855
    Abstract: The invention provides peptides that bind Tissue Factor Pathway Inhibitor (TFPI), including TFPI-inhibitory peptides, and compositions thereof. The peptides may be used to inhibit a TFPI, enhance thrombin formation in a clotting factor-deficient subject, increase blood clot formation in a subject, treat a blood coagulation disorder in a subject, purify TFPI, an identify a TFPI-binding compound.
    Type: Grant
    Filed: January 14, 2019
    Date of Patent: October 24, 2023
    Assignee: TAKEDA PHARMACEUTICAL COMPANY LIMITED
    Inventors: Michael Dockal, Rudolf Hartmann, Markus Fries, Friedrich Scheiflinger, Hartmut Ehrlich, Ulrich Reineke, Frank Osterkamp, Thomas Polakowski
  • Patent number: 11787796
    Abstract: The present invention provides compounds and compositions thereof which are useful as inhibitors of plasma kallikrein and which exhibit desirable characteristics for the same.
    Type: Grant
    Filed: September 17, 2020
    Date of Patent: October 17, 2023
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Nikolaos Papaioannou, Jeremy Mark Travins, Sarah Jocelyn Fink, John Mark Ellard, Alastair Rae
  • Patent number: 11786608
    Abstract: Disclosed is a complex of a compound of Formula 1, a stereoisomer thereof, or a tautomer of the compound of Formula 1 or stereoisomer thereof, and a cyclodextrin, in which the complex is an amorphous solid. This disclosure also relates to materials and methods for preparing the complex, to pharmaceutical compositions which contain the complex, and to the use of the complex to treat Type I hypersensitivity reactions, autoimmune diseases, inflammatory disorders, cancer, non-malignant proliferative disorders, and other conditions associated with BTK.
    Type: Grant
    Filed: January 8, 2021
    Date of Patent: October 17, 2023
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Rongliang Chen, Padma Manam, Lu Zeng
  • Publication number: 20230322669
    Abstract: The present invention provides a production method of a 3-cyanopyrrole compound possibly useful as an intermediate for pharmaceutical products. A production method of compound (II) including subjecting compound (I) to a reduction reaction, in which the aforementioned reduction reaction is continuous hydrogenation reaction in a fixed bed reactor filled with a supported metal catalyst. A production method of compound (III) including subjecting compound (I) to a reduction reaction followed by a cyclization reaction, in which the aforementioned reduction reaction is continuous hydrogenation reaction in a fixed bed reactor filled with a supported metal catalyst.
    Type: Application
    Filed: April 10, 2023
    Publication date: October 12, 2023
    Applicant: Takeda Pharmaceutical Company Limited
    Inventors: Takashi Ouchi, Giho Goh, Sunmi Kim, Jinsoon Choi, Hunsoo Park
  • Publication number: 20230322683
    Abstract: The present invention provides a compound having a cell degeneration inhibitory action, particularly a motor neuron degeneration inhibitory action, which is useful as an agent for the prophylaxis or treatment of motor neuron diseases (e.g., amyotrophic lateral sclerosis, progressive bulbar paralysis, progressive muscular atrophy, primary lateral sclerosis, progressive pseudobulbar paralysis, spinal muscular atrophy, Parkinson's disease, Lewy body dementia, multiple-system atrophy, Friedreich's ataxia) and the like. The present invention relates to a compound represented by the formula (I): wherein each symbol is as described in the specification, or a salt thereof.
    Type: Application
    Filed: October 15, 2020
    Publication date: October 12, 2023
    Applicant: Takeda Pharmaceutical Company Limited
    Inventors: Masashi TOYOFUKU, Yoshiteru ITO, Marilena PIRA, Takahiro SUGIMOTO
  • Patent number: 11780904
    Abstract: Among other aspects, the present invention relates to cell culture conditions for producing high molecular weight vWF, in particular, highly multimericWF with a high specific activity and ADAMTS13 with a high specific activity. The cell culture conditions of the present invention can include, for example, a cell culture medium with an increased copper concentration and/or cell culture supernatant with a low ammonium (NH4+) concentration. The present invention also provides methods for cultivating cells in the cell culture conditions to express high molecular weight vWF and rA13 having high specific activities.
    Type: Grant
    Filed: October 30, 2020
    Date of Patent: October 10, 2023
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Leopold Grillberger, Manfred Reiter, Wolfgang Mundt
  • Patent number: 11783931
    Abstract: A drug monitoring tool comprises a data receiver and an interactive user interface. The data receiver is configured to receive a pharmacokinetic (PK) profile of a patient. The interactive user interface is configured to display, to the patient, a time-varying therapeutic plasma protein level of the patient and delineate a plurality of zones within the interactive user interface associated with the time-varying therapeutic plasma protein level. The plurality of zones includes a safe zone indicating to the patient that the time-varying therapeutic plasma protein level is within a first concentration range considered safe for physical activity and a danger zone indicating to the patient that the time-varying therapeutic plasma protein level is within a second concentration range and physical activity should be limited.
    Type: Grant
    Filed: December 11, 2020
    Date of Patent: October 10, 2023
    Assignee: TAKEDA PHARMACEUTICAL COMPANY LIMITED
    Inventors: Gerald Spotts, Roman Pichler, Michael Nelson
  • Patent number: 11779635
    Abstract: This invention relates to methods of subcutaneous administration of ADAMTS13 formulations to a treat a disease or condition associated with ADAMTS13 and VWF dysfunction. Furthermore, evidence of the unexpectedly high bioavailability of ADAMTS13 formulations administered subcutaneously is provided herein.
    Type: Grant
    Filed: November 12, 2021
    Date of Patent: October 10, 2023
    Assignee: TAKEDA PHARMACEUTICAL COMPANY LIMITED
    Inventors: Alexandra Nathalie Kopic, Werner Hoellriegl, Barbara Plaimauer, Hanspeter Rottensteiner, Eva-Maria Muchitsch
  • Publication number: 20230312715
    Abstract: Provided herein are Conditional Bispecific Redirected Activation constructs, or COBRAs, that are administered in an active pro-drug format, which includes a human semm albumin (HSA) domain that increases its semm half-life. Upon exposure to tumor proteases, the constructs are cleaved and activated, such that they can bind both tumor target antigens (TTAs) as well as CD3, and thus recruiting T cells expressing CD3 to the tumor, resulting in treatment.
    Type: Application
    Filed: September 3, 2021
    Publication date: October 5, 2023
    Applicant: Takeda Pharmaceutical Company Limited
    Inventors: Robert B. DuBridge, Daniel J. Hicklin, Patricia A. Culp
  • Patent number: RE49686
    Abstract: The present invention relates to a compound represented by the formula wherein ring A is a nitrogen-containing heterocycle; ring B is an aromatic ring optionally having substituent(s); ring D is an aromatic ring optionally having substituent(s); L is a group represented by the formula R2, R3, R4a ? and R4b are each independently a hydrogen atom, an optionally halogenated C1-6 alkyl group or an optionally halogenated C3-6 cycloalkyl group, or R2 and R3 are optionally bonded via an alkylene chain or an alkenylene chain, or R4a and R4b are optionally bonded via an alkylene chain or an alkenylene chain; R1 is a hydrogen atom or a substituent; m and n are each independently an integer of 0 to 5; m+n is an integer of 2 to 5; and is a single bond or double bond, or a salt thereof; and the like.
    Type: Grant
    Filed: October 21, 2020
    Date of Patent: October 10, 2023
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Junya Shirai, Hideyuki Sugiyama, Taku Kamei, Hironobu Maezaki
  • Patent number: D1002837
    Type: Grant
    Filed: March 5, 2021
    Date of Patent: October 24, 2023
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Thomas Boyajian, Joseph M. Giamo, Anh Nguyen, Amey Mathakari